V920 (rVSV∆G-ZEBOV-GP) - Ebola

Merck's V920  (rVSVΔG-ZEBOV-GP)  candidate vaccine is a prime/boost candidate vaccine based on Ad26- and MVA-vectored components (Ad26.ZEBOV/MVA-BN-Filo) and the Ad5-EBOV candidate vaccine.

This experimental vaccine (rVSV∆G-ZEBOV-GP) has been given to approximately 54,000 healthcare workers in the DRC.

Recent clinical trial: African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola